½ÃÀ庸°í¼­
»óǰÄÚµå
1697960

¼¼°èÀÇ ºÐÀÚ °¨¿°Áõ °Ë»ç ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Çâ, ¾÷°è ºÐ¼® : Á¦Ç° ¹× ¼­ºñ½ºº°, À¯Çüº°, °Ë»ç À¯Çüº°, Áúȯº°, ±â¼úº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° - ½ÃÀå ¿¹Ãø(2025-2034³â)

Molecular Infectious Disease Testing Market Size, Share, Trends, Industry Analysis Report: By Product & Service, Type, Test Type, Disease, Technology, End User, and Region - Market Forecast, 2025-2034

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Polaris Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 129 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é ºÐÀÚ °¨¿°Áõ °Ë»ç ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö 347¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù. ÀÌ ¸®Æ÷Æ®´Â ÇöÀç ½ÃÀå ¿ªÇÐÀÇ »ó¼¼ ÀλçÀÌÆ®¿Í ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ °üÇÑ ºÐ¼®À» Á¦°øÇϰí ÀÖ½À´Ï´Ù.

ºÐÀÚ °¨¿°º´ °Ë»ç¶õ º´¿øÃ¼ÀÇ À¯Àü¹°ÁúÀ» °ËÃâ ¹× ºÐ¼®ÇÏ¿© Á¤È®Çϰí Á¶±â¿¡ Áúº´À» È®ÀÎÇÒ ¼ö Àִ ÷´Ü Áø´Ü ±â¼úÀ» ¸»ÇÕ´Ï´Ù. ºÐÀÚ °¨¿°º´ °Ë»ç ½ÃÀåÀÇ ÁÖ¿ä µ¿ÇâÀº ÇÑ ¹øÀÇ °Ë»ç·Î ¿©·¯ º´¿øÃ¼¸¦ µ¿½Ã¿¡ °ËÃâÇÒ ¼ö ÀÖ´Â ¸ÖƼÇ÷º½º ºÐÀÚÁø´Ü¹ýÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº Áø´Ü È¿À²À» Çâ»ó½Ã۰í, ³³±â¸¦ ´ÜÃà½Ã۸ç, ÀÓ»óÀû ÀÇ»ç°áÁ¤À» °³¼±ÇÕ´Ï´Ù. ƯÈ÷ ±Þ¼º±â ÀÇ·á ÇöÀå¿¡¼­ ½Å¼ÓÇÏ°í ±¤¹üÀ§ÇÑ Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ´ÙÁß ºÐ¼®ÀÌ ÀÏ»óÀûÀÎ ºÐÀÚ °Ë»ç¿¡ ÅëÇÕµÇ¾î °¨¿° °ü¸®¿¡¼­ ±× ¿ªÇÒÀÌ ´õ¿í °­È­µÇ°í ÀÖ½À´Ï´Ù.

ºÐÀÚ °¨¿° °Ë»ç ½ÃÀå ¼ö¿ä¸¦ Çü¼ºÇÏ´Â ¶Ç ´Ù¸¥ ÁÖ¿ä µ¿ÇâÀº Áø´Ü ¿öÅ©Ç÷ο쿡¼­ ÀÚµ¿È­¿Í ÀΰøÁö´É(AI)ÀÇ ÅëÇÕÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ÀÚµ¿È­µÈ ºÐÀÚ °Ë»ç Ç÷§ÆûÀº °Ë»ç½ÇÀÇ È¿À²¼ºÀ» °³¼±Çϰí ÀÎÀû ¿À·ù¸¦ ÃÖ¼ÒÈ­ÇÏ¸ç °Ë»ç ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇÒ ¼ö ÀÖ´Â È®À强À» Çâ»ó½Ã۰í, AI ±â¹Ý µ¥ÀÌÅÍ ºÐ¼®Àº °á°ú ÇØ¼®À» ´õ¿í Á¤±³ÇÏ°Ô ¸¸µé¾î º¸´Ù Á¤È®ÇÑ Áø´Ü°ú ¿¹Ãø ºÐ¼®À» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÚµ¿È­¿Í AIÀÇ °áÇÕÀº ºÐÀÚÁø´ÜÀ» °£¼ÒÈ­Çϰí, ´Ù¾çÇÑ ÀÇ·á ȯ°æ¿¡¼­ °Ë»ç¸¦ º¸´Ù ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ°í ½Å·ÚÇÒ ¼ö ÀÖ°Ô ÇÏ¿© ºÐÀÚ °¨¿° °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

ºÐÀÚ °¨¿° °Ë»ç ½ÃÀå : ºÐ¼® °³¿ä

Áúȯº°·Î´Â ¼ºº´(STD) ºÐ¾ß°¡ 2024³â ºÐÀÚ °¨¿° °Ë»ç ½ÃÀå Á¡À¯À²À» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ´Â STI ¹ßº´·ü Áõ°¡¿Í Á¤¹ÐÇÏ°í ºü¸¥ Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±âÀÎÇÑ °ÍÀ¸·Î ºÐ¼®µË´Ï´Ù.

Á¦Ç° ¹× ¼­ºñ½ºº°·Î´Â ½Ã¾à ¹× ŰƮ ºÐ¾ß°¡ ¿¹Ãø ±â°£ Áß °¡Àå ºü¸¥ ½ÃÀå ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ´Â ´Ù¾çÇÑ ÀÇ·á ȯ°æ¿¡¼­ ºÐÀÚÁø´Ü °Ë»çÀÇ »ç¿ë Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù.

ºÏ¹Ì´Â 2024³â ºÐÀÚ °¨¿° °Ë»ç ½ÃÀå ¸ÅÃâ Á¡À¯À² 1À§·Î ºÎ»óÇߴµ¥, ÀÌ´Â ÀÇ·á ÀÎÇÁ¶ó°¡ Àß °®Ãß¾îÁ® ÀÖ°í, ÷´Ü Áø´Ü ±â¼ú äÅ÷üÀÌ ³ôÀ¸¸ç, ºÐÀÚ °Ë»ç¸¦ Áö¿øÇÏ´Â ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©°¡ Àß °®Ãß¾îÁ® Àֱ⠶§¹®ÀÔ´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ºÐÀÚ °¨¿° °Ë»ç ½ÃÀåÀº ÀÇ·á ÅõÀÚ È®´ë, Áúº´ Á¶±â ¹ß°ß¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, °¨¿°¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¸¦ ¹è°æÀ¸·Î ¿¹Ãø ±â°£ Áß °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°èÀÇ ÁÖ¿ä ½ÃÀå Âü¿© ±â¾÷¿¡´Â Abbott, Danaher Corporation, bioMerieux SA, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Becton, Dickinson and Company, Hologic, Inc. (Gen-Probe), Illumina, Inc., Grifols S.A., Qiagen, Siemens Healthineers AG, Sysmex Corporation, Bruker Corporation, Thermo Fisher Scientific µîÀÌ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå °³¿ä

Á¦3Àå ºÐ¼® ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ ºÐÀÚ °¨¿°Áõ °Ë»ç ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ½º³À¼ô
  • ºÐÀÚ °¨¿°Áõ °Ë»ç ½ÃÀå ¿ªÇÐ
    • ÃËÁø¿äÀΰú ±âȸ
      • °¨¿°ÁõÀÇ Áõ°¡
      • ºÐÀÚÁø´Ü¿¡¼­ÀÇ ±Þ¼ÓÇÑ ±â¼ú Áøº¸
    • ¾ïÁ¦¿äÀΰú °úÁ¦
      • Àϰü¼º ¾ø´Â ȯ±Þ Á¤Ã¥
  • PESTLE ºÐ¼®
  • ºÐÀÚ °¨¿°Áõ °Ë»ç ½ÃÀå : À¯Åë ä³Î µ¿Çâ
  • ¹ë·ùüÀÎ ºÐ¼®

Á¦5Àå ¼¼°èÀÇ ºÐÀÚ °¨¿°Áõ °Ë»ç ½ÃÀå : Á¦Ç°¡¤¼­ºñ½ºº°

  • ÁÖ¿ä ºÐ¼® °á°ú
  • ¼­·Ð
  • ½Ã¾à¡¤Å°Æ®
  • ±â±â
  • ¼­ºñ½º¡¤¼ÒÇÁÆ®¿þ¾î

Á¦6Àå ¼¼°èÀÇ ºÐÀÚ °¨¿°Áõ °Ë»ç ½ÃÀå : À¯Çüº°

  • ÁÖ¿ä ºÐ¼® °á°ú
  • ¼­·Ð
  • ¸ÖƼÇ÷º½º °Ë»ç
  • ½Ì±ÛÇ÷º½º °Ë»ç

Á¦7Àå ¼¼°èÀÇ ºÐÀÚ °¨¿°Áõ °Ë»ç ½ÃÀå : °Ë»ç À¯Çüº°

  • ÁÖ¿ä ºÐ¼® °á°ú
  • ¼­·Ð
  • ÀÓ»ó °Ë»ç
  • PoC(Point-of-Care) °Ë»ç

Á¦8Àå ¼¼°èÀÇ ºÐÀÚ °¨¿°Áõ °Ë»ç ½ÃÀå : Áúȯº°

  • ÁÖ¿ä ºÐ¼® °á°ú
  • ¼­·Ð
  • È£Èí±â °¨¿°Áõ
  • ¼ÒÈ­±â °¨¿°Áõ
  • ¼º°¨¿°Áõ
  • ¿ø³»°¨¿°
  • Áú¿°
  • ¼ö¸·¿°
  • ¸Å°³¼º Áúȯ
  • ±âŸ °¨¿°Áõ

Á¦9Àå ¼¼°èÀÇ ºÐÀÚ °¨¿°Áõ °Ë»ç ½ÃÀå : ±â¼úº°

  • ÁÖ¿ä ºÐ¼® °á°ú
  • ¼­·Ð
  • ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ(PCR)
  • µî¿ÂÇÙ»êÁõÆø±â¼ú(INACT)
  • DNA ½ÃÄö½Ì¡¤Â÷¼¼´ë ½ÃÄö½Ì
  • in situ ÇÏÀ̺긮´ÙÀÌÁ¦À̼Ç
  • DNA ¸¶ÀÌÅ©·Î¾î·¹ÀÌ
  • ±âŸ

Á¦10Àå ¼¼°èÀÇ ºÐÀÚ °¨¿°Áõ °Ë»ç ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ÁÖ¿ä ºÐ¼® °á°ú
  • ¼­·Ð
  • Áø´Ü °Ë»ç½Ç
  • º´¿ø¡¤Áø·á¼Ò
  • ±âŸ

Á¦11Àå ¼¼°èÀÇ ºÐÀÚ °¨¿°Áõ °Ë»ç ½ÃÀå : Áö¿ªº°

  • ÁÖ¿ä ºÐ¼® °á°ú
  • ¼­·Ð
    • ºÐÀÚ °¨¿°Áõ °Ë»ç ½ÃÀå ºÐ¼® : Áö¿ªº°(2020-2034³â)
  • ºÏ¹Ì
    • ºÏ¹Ì : Á¦Ç°¡¤¼­ºñ½ºº°(2020-2034³â)
    • ºÏ¹Ì : À¯Çüº°(2020-2034³â)
    • ºÏ¹Ì : °Ë»ç À¯Çüº°(2020-2034³â)
    • ºÏ¹Ì : Áúȯº°(2020-2034³â)
    • ºÏ¹Ì : ±â¼úº°(2020-2034³â)
    • ºÏ¹Ì : ÃÖÁ¾»ç¿ëÀÚº°(2020-2034³â)
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • À¯·´ : Á¦Ç°¡¤¼­ºñ½ºº°(2020-2034³â)
    • À¯·´ : À¯Çüº°(2020-2034³â)
    • À¯·´ : °Ë»ç À¯Çüº°(2020-2034³â)
    • À¯·´ : Áúȯº°(2020-2034³â)
    • À¯·´ : ±â¼úº°(2020-2034³â)
    • À¯·´ : ÃÖÁ¾»ç¿ëÀÚº°(2020-2034³â)
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³×´ú¶õµå
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : Á¦Ç°¡¤¼­ºñ½ºº°, 2020-2034³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : À¯Çüº°(2020-2034³â)
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : °Ë»ç À¯Çüº°(2020-2034³â)
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : Áúȯº°(2020-2034³â)
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±â¼úº°(2020-2034³â)
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ÃÖÁ¾»ç¿ëÀÚº°(2020-2034³â)
    • Áß±¹
    • Àεµ
    • ¸»·¹À̽þÆ
    • ÀϺ»
    • Àεµ³×½Ã¾Æ
    • Çѱ¹
    • È£ÁÖ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : Á¦Ç°¡¤¼­ºñ½ºº°(2020-2034³â)
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : À¯Çüº°(2020-2034³â)
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : °Ë»ç À¯Çüº°(2020-2034³â)
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : Áúȯº°(2020-2034³â)
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±â¼úº°(2020-2034³â)
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ÃÖÁ¾»ç¿ëÀÚº°(2020-2034³â)
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä« : Á¦Ç°¡¤¼­ºñ½ºº°(2020-2034³â)
    • ¶óƾ¾Æ¸Þ¸®Ä« : À¯Çüº°(2020-2034³â)
    • ¶óƾ¾Æ¸Þ¸®Ä« : °Ë»ç À¯Çüº°(2020-2034³â)
    • ¶óƾ¾Æ¸Þ¸®Ä« : Áúȯº°(2020-2034³â)
    • ¶óƾ¾Æ¸Þ¸®Ä« : ±â¼úº°(2020-2034³â)
    • ¶óƾ¾Æ¸Þ¸®Ä« : ÃÖÁ¾»ç¿ëÀÚº°(2020-2034³â)
    • ¸ß½ÃÄÚ
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«

Á¦12Àå °æÀï ±¸µµ

  • »ç¾÷ È®´ë¡¤±â¾÷ Àμö ºÐ¼®
    • »ç¾÷ È®´ë
    • ±â¾÷ Àμö
  • Á¦ÈÞ/Çù¾÷/ÇÕÀÇ/°ø°³

Á¦13Àå ±â¾÷ °³¿ä

  • Abbott
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • bioMérieux SA
  • Bio-Rad Laboratories, Inc.
  • Bruker Corporation
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • Grifols S.A.
  • Hologic, Inc.(Gen-Probe)
  • Illumina, Inc.
  • Qiagen
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific
KSA 25.05.07

The molecular infectious disease testing market size is expected to reach USD 34.73 billion by 2034, according to a new study by Polaris Market Research. The report "Molecular Infectious Disease Testing Market Share, Size, Trends, Industry Analysis Report: By Product & Service, Type (Multiplex Testing and Singleplex Testing), Test Type, Disease, Technology, End User, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Molecular infectious disease testing refers to advanced diagnostic techniques that detect and analyze the genetic material of pathogens to enable precise and early disease identification. A major molecular infectious disease testing market trend is the increasing adoption of multiplex molecular diagnostics, which allow the simultaneous detection of multiple pathogens in a single test. This advancement improves diagnostic efficiency, reduces turnaround time, and improves clinical decision-making. The growing demand for rapid and wide diagnostic solutions, particularly in acute care settings, is further driving the integration of multiplex assays into routine molecular testing, strengthening their role in infectious disease management.

Another major trend shaping the molecular infectious disease testing market demand is the rising integration of automation and artificial intelligence (AI) in diagnostic workflows. Automated molecular testing platforms are improving laboratory efficiency, minimizing human errors, and improving scalability to meet the increasing testing demand. AI-driven data analysis is further refining result interpretation, facilitating more accurate diagnoses and predictive analytics. The combination of automation and AI is streamlining molecular diagnostics, making testing more accessible and reliable across various healthcare settings, thereby accelerating molecular infectious disease testing market growth.

Molecular Infectious Disease Testing Market Report Highlights

In terms of disease, the sexually transmitted disease (STD) segment led the molecular infectious disease testing market share in 2024, driven by the rising incidence of STIs and the growing need for precise and early diagnostic solutions.

Based on product & service, the reagents & kits segment is anticipated to experience the most rapid growth in the market during the forecast period, fueled by the increasing utilization of molecular diagnostic tests across various healthcare settings.

North America emerged as the leading region in the global molecular infectious disease testing market revenue share in 2024, attributed to its well-developed healthcare infrastructure, high adoption of advanced diagnostic technologies, and a robust regulatory framework supporting molecular testing.

The molecular infectious disease testing market in Asia Pacific is expected to witness the highest growth rate during the forecast period, driven by expanding healthcare investments, greater awareness of early disease detection, and a rising prevalence of infectious diseases.

A few global key market players include Abbott; Danaher Corporation; bioMerieux SA; F. Hoffmann-La Roche Ltd; Bio-Rad Laboratories, Inc.; Agilent Technologies, Inc.; Becton, Dickinson and Company; Hologic, Inc. (Gen-Probe); Illumina, Inc., Grifols S.A.; Qiagen; Siemens Healthineers AG; Sysmex Corporation; Bruker Corporation; and Thermo Fisher Scientific.

Polaris Market Research has segmented the molecular infectious disease testing market report on the basis of product & service, type, test type, disease, technology, end user, and region:

By Product & Service Outlook (Revenue, USD Billion, 2020-2034)

  • Reagents & Kits
  • Instruments
  • Services & Software

By Type Outlook (Revenue, USD Billion, 2020-2034)

  • Multiplex Testing
  • Singleplex Testing

By Test Type Outlook (Revenue, USD Billion, 2020-2034)

  • Laboratory Tests
  • Point-of-Care Tests

By Disease Outlook (Revenue, USD Billion, 2020-2034)

  • Respiratory Infectious Diseases
  • Gastrointestinal Infectious Diseases
  • Sexually Transmitted Diseases
  • Hospital-Acquired Infections
  • Vaginitis
  • Meningitis
  • Vector-Borne Diseases
  • Other Infectious Diseases

By Technology Outlook (Revenue, USD Billion, 2020-2034)

  • Polymerase Chain Reaction
  • Isothermal Nucleic Acid Amplification Technology
  • DNA-Sequencing & Next-Generation Sequencing
  • In-Situ Hybridization
  • DNA Microarrays
  • Others

By End User Outlook (Revenue, USD Billion, 2020-2034)

  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Others

By Regional Outlook (Revenue, USD Billion, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Vietnam
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Molecular Infectious Disease Testing Market Insights

  • 4.1. Molecular Infectious Disease Testing Market - Distribution Channel Snapshot
  • 4.2. Molecular Infectious Disease Testing Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Cases of Infectious Diseases
      • 4.2.1.2. Rapid Technological Advancements in Molecular Diagnostics
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Inconsistent Reimbursement Policies
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Molecular Infectious Disease Testing Market Distribution Channel Trends
  • 4.6. Value Chain Analysis

5. Global Molecular Infectious Disease Testing Market, by Product & Service

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
  • 5.3. Reagents & Kits
    • 5.3.1. Global Molecular Infectious Disease Testing Market, by Pan-based Molecular Infectious Disease Testing, by Region, 2020-2034 (USD Billion)
  • 5.4. Instruments
    • 5.4.1. Global Molecular Infectious Disease Testing Market, by Instruments, by Region, 2020-2034 (USD Billion)
  • 5.5. Services & Software
    • 5.5.1. Global Molecular Infectious Disease Testing Market, by Services & Software, by Region, 2020-2034 (USD Billion)

6. Global Molecular Infectious Disease Testing Market, by Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
  • 6.3. Multiplex Testing
    • 6.3.1. Global Molecular Infectious Disease Testing Market, by Multiplex Testing, by Region, 2020-2034 (USD Billion)
  • 6.4. Singleplex Testing
    • 6.4.1. Global Molecular Infectious Disease Testing Market, by Singleplex Testing, by Region, 2020-2034 (USD Billion)

7. Global Molecular Infectious Disease Testing Market, by Test Type

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
  • 7.3. Laboratory Tests
    • 7.3.1. Global Molecular Infectious Disease Testing Market, by Laboratory Tests, by Region, 2020-2034 (USD Billion)
  • 7.4. Point-of-Care Tests
    • 7.4.1. Global Molecular Infectious Disease Testing Market, by Point-of-Care Tests, by Region, 2020-2034 (USD Billion)

8. Global Molecular Infectious Disease Testing Market, by Disease

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
  • 8.3. Respiratory Infectious Diseases
    • 8.3.1. Global Molecular Infectious Disease Testing Market, by Respiratory Infectious Diseases, by Region, 2020-2034 (USD Billion)
  • 8.4. Gastrointestinal Infectious Diseases
    • 8.4.1. Global Molecular Infectious Disease Testing Market, by Gastrointestinal Infectious Diseases, by Region, 2020-2034 (USD Billion)
  • 8.5. Sexually Transmitted Diseases
    • 8.5.1. Global Molecular Infectious Disease Testing Market, by Sexually Transmitted Diseases, by Region, 2020-2034 (USD Billion)
  • 8.6. Hospital-Acquired Infections
    • 8.6.1. Global Molecular Infectious Disease Testing Market, by Hospital-Acquired Infections, by Region, 2020-2034 (USD Billion)
  • 8.7. Vaginitis
    • 8.7.1. Global Molecular Infectious Disease Testing Market, by Vaginitis Diseases, by Region, 2020-2034 (USD Billion)
  • 8.8. Meningitis
    • 8.8.1. Global Molecular Infectious Disease Testing Market, by Meningitis, by Region, 2020-2034 (USD Billion)
  • 8.9. Vector-Borne Diseases
    • 8.9.1. Global Molecular Infectious Disease Testing Market, by Vector-Borne Diseases, by Region, 2020-2034 (USD Billion)
  • 8.10. Other Infectious Diseases
    • 8.10.1. Global Molecular Infectious Disease Testing Market, by Other Infectious Diseases, by Region, 2020-2034 (USD Billion)

9. Global Molecular Infectious Disease Testing Market, by Technology

  • 9.1. Key Findings
  • 9.2. Introduction
    • 9.2.1. Global Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
  • 9.3. Polymerase Chain Reaction
    • 9.3.1. Global Molecular Infectious Disease Testing Market, by Polymerase Chain Reaction, by Region, 2020-2034 (USD Billion)
  • 9.4. Isothermal Nucleic Acid Amplification Technology
    • 9.4.1. Global Molecular Infectious Disease Testing Market, by Isothermal Nucleic Acid Amplification Technology, by Region, 2020-2034 (USD Billion)
  • 9.5. DNA-Sequencing & Next-Generation Sequencing
    • 9.5.1. Global Molecular Infectious Disease Testing Market, by DNA-Sequencing & Next-Generation Sequencing, by Region, 2020-2034 (USD Billion)
  • 9.6. In-Situ Hybridization
    • 9.6.1. Global Molecular Infectious Disease Testing Market, by In-Situ Hybridization, by Region, 2020-2034 (USD Billion)
  • 9.7. DNA Microarrays
    • 9.7.1. Global Molecular Infectious Disease Testing Market, by DNA Microarrays, by Region, 2020-2034 (USD Billion)
  • 9.8. Others
    • 9.8.1. Global Molecular Infectious Disease Testing Market, by Others, by Region, 2020-2034 (USD Billion)

10. Global Molecular Infectious Disease Testing Market, by End User

  • 10.1. Key Findings
  • 10.2. Introduction
    • 10.2.1. Global Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
  • 10.3. Diagnostic Laboratories
    • 10.3.1. Global Molecular Infectious Disease Testing Market, by Diagnostic Laboratories, by Region, 2020-2034 (USD Billion)
  • 10.4. Hospitals & Clinics
    • 10.4.1. Global Molecular Infectious Disease Testing Market, by Hospitals & Clinics, by Region, 2020-2034 (USD Billion)
  • 10.5. Others
    • 10.5.1. Global Molecular Infectious Disease Testing Market, by Others, by Region, 2020-2034 (USD Billion)

11. Global Molecular Infectious Disease Testing Market, by Geography

  • 11.1. Key Findings
  • 11.2. Introduction
    • 11.2.1. Molecular Infectious Disease Testing Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 11.3. Molecular Infectious Disease Testing Market - North America
    • 11.3.1. North America: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
    • 11.3.2. North America: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
    • 11.3.3. North America: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
    • 11.3.4. North America: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
    • 11.3.5. North America: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
    • 11.3.6. North America: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.3.7. Molecular Infectious Disease Testing Market - US
      • 11.3.7.1. US: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.3.7.2. US: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.3.7.3. US: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.3.7.4. US: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.3.7.5. US: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.3.7.6. US: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.3.8. Molecular Infectious Disease Testing Market - Canada
      • 11.3.8.1. Canada: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.3.8.2. Canada: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.3.8.3. Canada: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.3.8.4. Canada: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.3.8.5. Canada: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.3.8.6. Canada: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
  • 11.4. Molecular Infectious Disease Testing Market - Europe
    • 11.4.1. Europe: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
    • 11.4.2. Europe: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
    • 11.4.3. Europe: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
    • 11.4.4. Europe: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
    • 11.4.5. Europe: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
    • 11.4.6. Europe: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.4.7. Molecular Infectious Disease Testing Market - UK
      • 11.4.7.1. UK: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.4.7.2. UK: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.4.7.3. UK: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.4.7.4. UK: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.4.7.5. UK: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.4.7.6. UK: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.4.8. Molecular Infectious Disease Testing Market - France
      • 11.4.8.1. France: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.4.8.2. France: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.4.8.3. France: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.4.8.4. France: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.4.8.5. France: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.4.8.6. France: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.4.9. Molecular Infectious Disease Testing Market - Germany
      • 11.4.9.1. Germany: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.4.9.2. Germany: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.4.9.3. Germany: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.4.9.4. Germany: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.4.9.5. Germany: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.4.9.6. Germany: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.4.10. Molecular Infectious Disease Testing Market - Italy
      • 11.4.10.1. Italy: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.4.10.2. Italy: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.4.10.3. Italy: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.4.10.4. Italy: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.4.10.5. Italy: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.4.10.6. Italy: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.4.11. Molecular Infectious Disease Testing Market - Spain
      • 11.4.11.1. Spain: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.4.11.2. Spain: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.4.11.3. Spain: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.4.11.4. Spain: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.4.11.5. Spain: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.4.11.6. Spain: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.4.12. Molecular Infectious Disease Testing Market - Netherlands
      • 11.4.12.1. Netherlands: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.4.12.2. Netherlands: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.4.12.3. Netherlands: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.4.12.4. Netherlands: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.4.12.5. Netherlands: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.4.12.6. Netherlands: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.4.13. Molecular Infectious Disease Testing Market - Russia
      • 11.4.13.1. Russia: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.4.13.2. Russia: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.4.13.3. Russia: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.4.13.4. Russia: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.4.13.5. Russia: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.4.13.6. Russia: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.4.14. Molecular Infectious Disease Testing Market - Rest of Europe
      • 11.4.14.1. Rest of Europe: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.4.14.2. Rest of Europe: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.4.14.3. Rest of Europe: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.4.14.4. Rest of Europe: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.4.14.5. Rest of Europe: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.4.14.6. Rest of Europe: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
  • 11.5. Molecular Infectious Disease Testing Market - Asia Pacific
    • 11.5.1. Asia Pacific: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
    • 11.5.2. Asia Pacific: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
    • 11.5.3. Asia Pacific: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
    • 11.5.4. Asia Pacific: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
    • 11.5.5. Asia Pacific: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
    • 11.5.6. Asia Pacific: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.5.7. Molecular Infectious Disease Testing Market - China
      • 11.5.7.1. China: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.5.7.2. China: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.5.7.3. China: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.5.7.4. China: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.5.7.5. China: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.5.7.6. China: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.5.8. Molecular Infectious Disease Testing Market - India
      • 11.5.8.1. India: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.5.8.2. India: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.5.8.3. India: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.5.8.4. India: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.5.8.5. India: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.5.8.6. India: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.5.9. Molecular Infectious Disease Testing Market - Malaysia
      • 11.5.9.1. Malaysia: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.5.9.2. Malaysia: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.5.9.3. Malaysia: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.5.9.4. Malaysia: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.5.9.5. Malaysia: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.5.9.6. Malaysia: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.5.10. Molecular Infectious Disease Testing Market - Japan
      • 11.5.10.1. Japan: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.5.10.2. Japan: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.5.10.3. Japan: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.5.10.4. Japan: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.5.10.5. Japan: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.5.10.6. Japan: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.5.11. Molecular Infectious Disease Testing Market - Indonesia
      • 11.5.11.1. Indonesia: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.5.11.2. Indonesia: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.5.11.3. Indonesia: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.5.11.4. Indonesia: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.5.11.5. Indonesia: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.5.11.6. Indonesia: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.5.12. Molecular Infectious Disease Testing Market - South Korea
      • 11.5.12.1. South Korea: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.5.12.2. South Korea: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.5.12.3. South Korea: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.5.12.4. South Korea: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.5.12.5. South Korea: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.5.12.6. South Korea: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.5.13. Molecular Infectious Disease Testing Market - Australia
      • 11.5.13.1. Australia: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.5.13.2. Australia: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.5.13.3. Australia: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.5.13.4. Australia: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.5.13.5. Australia: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.5.13.6. Australia: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.5.14. Molecular Infectious Disease Testing Market - Rest of Asia Pacific
      • 11.5.14.1. Rest of Asia Pacific: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.5.14.2. Rest of Asia Pacific: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.5.14.3. Rest of Asia Pacific: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.5.14.4. Rest of Asia Pacific: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.5.14.5. Rest of Asia Pacific: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.5.14.6. Rest of Asia Pacific: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
  • 11.6. Molecular Infectious Disease Testing Market - Middle East & Africa
    • 11.6.1. Middle East & Africa: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
    • 11.6.2. Middle East & Africa: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
    • 11.6.3. Middle East & Africa: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
    • 11.6.4. Middle East & Africa: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
    • 11.6.5. Middle East & Africa: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
    • 11.6.6. Middle East & Africa: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.6.7. Molecular Infectious Disease Testing Market - Saudi Arabia
      • 11.6.7.1. Saudi Arabia: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.6.7.2. Saudi Arabia: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.6.7.3. Saudi Arabia: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.6.7.4. Saudi Arabia: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.6.7.5. Saudi Arabia: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.6.7.6. Saudi Arabia: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.6.8. Molecular Infectious Disease Testing Market - UAE
      • 11.6.8.1. UAE: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.6.8.2. UAE: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.6.8.3. UAE: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.6.8.4. UAE: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.6.8.5. UAE: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.6.8.6. UAE: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.6.9. Molecular Infectious Disease Testing Market - Israel
      • 11.6.9.1. Israel: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.6.9.2. Israel: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.6.9.3. Israel: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.6.9.4. Israel: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.6.9.5. Israel: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.6.9.6. Israel: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.6.10. Molecular Infectious Disease Testing Market - South Africa
      • 11.6.10.1. South Africa: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.6.10.2. South Africa: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.6.10.3. South Africa: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.6.10.4. South Africa: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.6.10.5. South Africa: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.6.10.6. South Africa: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.6.11. Molecular Infectious Disease Testing Market - Rest of Middle East & Africa
      • 11.6.11.1. Rest of Middle East & Africa: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.6.11.2. Rest of Middle East & Africa: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.6.11.3. Rest of Middle East & Africa: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.6.11.4. Rest of Middle East & Africa: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.6.11.5. Rest of Middle East & Africa: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.6.11.6. Rest of Middle East & Africa: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
  • 11.7. Molecular Infectious Disease Testing Market - Latin America
    • 11.7.1. Latin America: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
    • 11.7.2. Latin America: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
    • 11.7.3. Latin America: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
    • 11.7.4. Latin America: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
    • 11.7.5. Latin America: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
    • 11.7.6. Latin America: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.7.7. Molecular Infectious Disease Testing Market - Mexico
      • 11.7.7.1. Mexico: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.7.7.2. Mexico: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.7.7.3. Mexico: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.7.7.4. Mexico: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.7.7.5. Mexico: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.7.7.6. Mexico: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.7.8. Molecular Infectious Disease Testing Market - Brazil
      • 11.7.8.1. Brazil: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.7.8.2. Brazil: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.7.8.3. Brazil: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.7.8.4. Brazil: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.7.8.5. Brazil: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.7.8.6. Brazil: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.7.9. Molecular Infectious Disease Testing Market - Argentina
      • 11.7.9.1. Argentina: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.7.9.2. Argentina: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.7.9.3. Argentina: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.7.9.4. Argentina: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.7.9.5. Argentina: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.7.9.6. Argentina: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)
    • 11.7.10. Molecular Infectious Disease Testing Market - Rest of Latin America
      • 11.7.10.1. Rest of Latin America: Molecular Infectious Disease Testing Market, by Product & Service, 2020-2034 (USD Billion)
      • 11.7.10.2. Rest of Latin America: Molecular Infectious Disease Testing Market, by Type, 2020-2034 (USD Billion)
      • 11.7.10.3. Rest of Latin America: Molecular Infectious Disease Testing Market, by Test Type, 2020-2034 (USD Billion)
      • 11.7.10.4. Rest of Latin America: Molecular Infectious Disease Testing Market, by Disease, 2020-2034 (USD Billion)
      • 11.7.10.5. Rest of Latin America: Molecular Infectious Disease Testing Market, by Technology, 2020-2034 (USD Billion)
      • 11.7.10.6. Rest of Latin America: Molecular Infectious Disease Testing Market, by End User, 2020-2034 (USD Billion)

12. Competitive Landscape

  • 12.1. Expansion and Acquisition Analysis
    • 12.1.1. Expansion
    • 12.1.2. Acquisitions
  • 12.2. Partnerships/Collaborations/Agreements/Exhibitions

13. Company Profiles

  • 13.1. Abbott
    • 13.1.1. Company Overview
    • 13.1.2. Financial Performance
    • 13.1.3. Product Benchmarking
    • 13.1.4. Recent Development
  • 13.2. Agilent Technologies, Inc.
    • 13.2.1. Company Overview
    • 13.2.2. Financial Performance
    • 13.2.3. Product Benchmarking
    • 13.2.4. Recent Development
  • 13.3. Becton, Dickinson and Company
    • 13.3.1. Company Overview
    • 13.3.2. Financial Performance
    • 13.3.3. Product Benchmarking
    • 13.3.4. Recent Development
  • 13.4. bioMérieux SA
    • 13.4.1. Company Overview
    • 13.4.2. Financial Performance
    • 13.4.3. Product Benchmarking
    • 13.4.4. Recent Development
  • 13.5. Bio-Rad Laboratories, Inc.
    • 13.5.1. Company Overview
    • 13.5.2. Financial Performance
    • 13.5.3. Product Benchmarking
    • 13.5.4. Recent Development
  • 13.6. Bruker Corporation
    • 13.6.1. Company Overview
    • 13.6.2. Financial Performance
    • 13.6.3. Product Benchmarking
    • 13.6.4. Recent Development
  • 13.7. Danaher Corporation
    • 13.7.1. Company Overview
    • 13.7.2. Financial Performance
    • 13.7.3. Product Benchmarking
    • 13.7.4. Recent Development
  • 13.8. F. Hoffmann-La Roche Ltd
    • 13.8.1. Company Overview
    • 13.8.2. Financial Performance
    • 13.8.3. Product Benchmarking
    • 13.8.4. Recent Development
  • 13.9. Grifols S.A.
    • 13.9.1. Company Overview
    • 13.9.2. Financial Performance
    • 13.9.3. Product Benchmarking
    • 13.9.4. Recent Development
  • 13.10. Hologic, Inc. (Gen-Probe)
    • 13.10.1. Company Overview
    • 13.10.2. Financial Performance
    • 13.10.3. Product Benchmarking
    • 13.10.4. Recent Development
  • 13.11. Illumina, Inc.
    • 13.11.1. Company Overview
    • 13.11.2. Financial Performance
    • 13.11.3. Product Benchmarking
    • 13.11.4. Recent Development
  • 13.12. Qiagen
    • 13.12.1. Company Overview
    • 13.12.2. Financial Performance
    • 13.12.3. Product Benchmarking
    • 13.12.4. Recent Development
  • 13.13. Siemens Healthineers AG
    • 13.13.1. Company Overview
    • 13.13.2. Financial Performance
    • 13.13.3. Product Benchmarking
    • 13.13.4. Recent Development
  • 13.14. Sysmex Corporation
    • 13.14.1. Company Overview
    • 13.14.2. Financial Performance
    • 13.14.3. Product Benchmarking
    • 13.14.4. Recent Development
  • 13.15. Thermo Fisher Scientific
    • 13.15.1. Company Overview
    • 13.15.2. Financial Performance
    • 13.15.3. Product Benchmarking
    • 13.15.4. Recent Development
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦